Toward a Computationally-Informed, Personalized Treatment for Hallucinations
Recruiting · NCT04366518 · Interventional (participants receive a specific treatment) · Lead sponsor: Yale University
View the official record on ClinicalTrials.gov →Interventions studied
Placebo PatchRivastigmine Transdermal SystemScopolamine
What this trial is about
Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Early Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age 18-65
- English speaking
- Right handedness
- Diagnosed with schizophrenia schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder
- History of auditory verbal hallucinations occurring at least weekly
Exclusion criteria
- Current substance dependence or active use as determined by drug test.
- Any neurological, medical or developmental problem that is known to impair cognition significantly
- Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia
- History of seizures
- History of violence
- History of suicide
- Pregnancy (determined by urine pregnancy test)
- Concurrent participation in any other intervention study
- History of urinary retention
- History of delirium
- Current use of any cholinergic or anticholinergic medication
- History of asthma, diabetes, and cardiovascular disease
- Evidence of cardiovascular disease on EKG
- Individuals who have been on dopamine-2 antagonists for less than 6 months (to limit risk of EPS)
Where it is running
1 location listed across 1 US state.
- Connecticut Mental Health Center - New Haven, Connecticut, United States